FOI 2024-304

Name of medicine

Number patients treated

1.1 Fedratinib (Inrebic)

<5

1.2 Momelotinib (Omjjara)

NIL

1.3 Ruxolitinib (Jakavi)

7

1.4 Hydroxycarbamide

166

Diagnosis with ICD10 codes

Number patients treated

2.1 Polycythaemia vera

ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3

According to iQemo we have 9 patients treating for polycythaemia vera, this will not include the treatment of “low-risk” patient’s who may be treating using low-dose aspirin which would not be prescribed on our systems.

2.2 Myelofibrosis

ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3

According to iQemo we have 22 patients treating for myelofibrosis, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin.

2.3 Essential thrombocythemia

ICD10 code = D473, D47.3 OR morphology code = 9962/3

According to iQemo we have 33 patients treating for essential thrombocythemia, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin. 

2.4 Myeloproliferative Disease, Chronic

ICD10 code = D471, D47.1

According to iQemo we have 134 patients treating for myeloproliferative disease, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin.

Name of medicine

Number patients treated

3.1 Fedratinib (Inrebic)

<5

3.2 Momelotinib (Omjjara)

NIL

3.3 Ruxolitinib (Jakavi)

6

3.4 Hydroxycarbamide

15

3.5 Peginterferon Alfa-2a (Pegasys)

NIL

3.6 Ropeginterferon Alfa-2b (Besremi)

NIL

3.7 Epoetin alfa (Eprex, Binocrit)

NIL

3.8 Epoetin beta (NeoRecormon, Mircera)

NIL

3.9 Epoetin zeta (Retacrit)

NIL

3.10 Darbepoetin (Aranesp)

NIL

3.11 No active treatment

<5

3.12 Allogeneic stem cell transplant

This is not offered at ELHT.

Name of medicine

Number patients treated

4.0 Ruxolitinib (Jakavi) + epoetin

NIL

Name of medicine

Number patients treated

5.1 Acalabrutinib (Calquence)

29

5.2 Ibrutinib (Imbruvica)

16

5.3 Pirtobrutinib (Jaypirca)

NIL

5.4 Venetoclax (Venclyxto)

14

5.5 Zanubrutinib (Brukinsa)

<5

Name of medicine

Number patients treated

6.1 Acalabrutinib (Calquence)

29

6.2 Ibrutinib (Imbruvica)

16

6.3 Pirtobrutinib (Jaypirca)

NIL

6.4 Venetoclax (Venclyxto)

14

6.5 Zanubrutinib (Brukinsa)

<5

Name of monotherapy or combination

Number patients treated

7.1 Ibrutinib + venetoclax

5

7.2 Obinutuzumab + venetoclax

<5

7.3 Acalabrutinib monotherapy / maintenance

29

7.4 Zanubrutinib monotherapy / maintenance

<5

7.5 Ibrutinib monotherapy / maintenance

11

7.6 Venetoclax monotherapy

NIL

7.7 Venetoclax + rituximab

5

Number patients treated

8.0 Treated for Mantle Cell Lymphoma

9

Name of medicine

Number patients treated

8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol

NIL

8.2 Stem Cell Transplant

This is not offered at ELHT.

8.3 Rituximab + bendamustine + cytarabine

NIL

8.4 Rituximab + bendamustine

NIL

8.5 Ibrutinib

<5

8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo

<5

8.7 Acalabrutinib + rituximab + bendamustine

NIL